TIDMIMM
RNS Number : 6371V
Immupharma PLC
11 August 2022
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR
INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES,
CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY
OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY
APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR A
SOLICITATION TO BUY SECURITIES IN ANY JURISDICTION, INCLUDING THE
UNITED STATES, CANADA, AUSTRALIA, JAPAN AND THE REPUBLIC OF SOUTH
AFRICA. NEITHER THIS ANNOUNCEMENT NOR ANYTHING CONTAINED HEREIN
SHALL FORM THE BASIS OF, OR BE RELIED UPON IN CONNECTION WITH, ANY
OFFER OR COMMITMENT WHATSOEVER IN ANY JURISDICTION.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES
OF ARTICLE 7 OF REGULATION 2014/596/EU. IN ADDITION, MARKET
SOUNDINGS WERE TAKEN IN RESPECT OF THE MATTERS CONTAINED IN THIS
ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF
SUCH INSIDE INFORMATION. UPON THE PUBLICATION OF THIS ANNOUNCEMENT,
THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC
DOMAIN AND SUCH PERSONS SHALL THEREFORE CEASE TO BE IN POSSESSION
OF INSIDE INFORMATION.
11 August 2022
ImmuPharma plc
Result of Broker Option / PDMR Dealings
ImmuPharma plc ("ImmuPharma" or "the Company"), announces that
it has raised GBP0.95 million (before expenses) pursuant to a
Broker Option following the announcement made on 3 August 2022.
Under the terms of a placing agreement entered into by the
Company with Stanford Capital Partners Limited ("SCP") and SPARK
Advisory Partners Limited on 3 August, the Company granted an
option to SCP to enable it to deal with additional demand under the
Placing in the event that requests to participate in the Placing
from qualifying investors were received during the period from the
time of the announcement of the Placing up to 5.00 p.m. on 10
August 2022, up to a maximum of GBP1.3 million ("Broker Option").
SCP has exercised its Broker Option in respect of 19 million Broker
Option Shares at the same price as the Placing.
Accordingly, the total number of Broker Option Shares to be
issued by the Company pursuant to the Broker Option is 19 million.
The aggregate gross proceeds of the Placing and the Broker Option
is GBP1.04 million. Aggregate proceeds, net of expenses, are
expected to be approximately GBP0.97 million.
Certain directors of the Company have subscribed for shares in
the Broker Option as set out below:
Name of Director No of Broker Number of % of Ordinary Share Capital
Option Shares Ordinary Shares (as enlarged by the issue
subscribed held post of the Lanstead Subscription
Admission Shares, the Placing Shares,
the Broker Option Shares,
the Value Payment Shares
and the Fee Shares)
Tim McCarthy 1,200,000 1,488,462 0 .46%
--------------- ----------------- ------------------------------
Tim Franklin 400,000 525,000 0 .16%
--------------- ----------------- ------------------------------
Lisa Baderoon 400,000 583,963 0 .18%
--------------- ----------------- ------------------------------
The Company will issue, conditional upon Admission, warrants to
subscribe for a total of 1 million new Ordinary Shares at the Issue
Price for a period of 10 years from Admission to Stanford Capital
Partners (0.5 million) and SI Capital (0.5 million).
Further to the announcement of 3 August 2022, the Directors
confirm that the fundraising, together with existing funding and
funding arrangements, will provide the Company with sufficient
working capital for at least the next 12 months.
This is based on the assumptions detailed in the announcement of
3 August 2022 and the Directors undertaking active measures to
limit or defer cash outflows from the business in the near term,
(which include the Directors deferring a proportion of their
salaries) until such time as the business is able to meet these
payments.
Settlement and dealings
Once issued, the rights of Broker Option Shares will rank pari
passu with the Company's existing Ordinary Shares.
An application will be made for the Broker Option Shares to be
admitted to trading on AIM. Dealings in the
Broker Option Shares on AIM are expected to commence at 8:00 a.m. on or around 16 August 2022 .
Total Voting Rights
Fo llowing Admission, the Company's issued share capital will
comprise 325,803,104 Ordinary Shares with one voting right each and
284,984,933 deferred shares with no rights to vote. As the Company
does not hold any shares in treasury, the total number of voting
rights in the Company is also 325,803,104 and this figure of
Ordinary Shares may be used by shareholders as the denominator for
the calculations by which they will determine if they are required
to notify their interest in, or a change to their interest in, the
share capital of the Company under the FCA's Disclosure Guidance
and Transparency Rules.
Capitalised terms used in this announcement have the meanings
given to them in the announcement of the Lanstead Subscription and
Placing on 3 August 2022.
**S**
For further information, please contact:
ImmuPharma PLC ( www.immupharma.com )
Tim McCarthy, Chief Executive Officer &
Chairman + 44 (0) 207 152 4080
Lisa Baderoon, Head of Investor Relations
& Non-Executive Director + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD) +44 (0) 203 36 8 3550
Neil Baldwin
Stanford Capital Partners (Joint Broker) +44 20 3650 3650
Patrick Claridge
John Howes
Bob Pountney
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Tim McCarthy
-------------------------------------- ----------------------------------------
2 Reason for the notification
--------------------------------------------------------------------------------
a) Position / status Chairman and Chief Executive Officer
-------------------------------------- ----------------------------------------
b) Initial notification Initial notification
/ Amendment
-------------------------------------- ----------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------------
a) Name ImmuPharma PLC
-------------------------------------- ----------------------------------------
b) LEI 213800VZKGHXC7VUS895
-------------------------------------- ----------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
--------------------------------------------------------------------------------
a) Description of the Ordinary Shares of 1p each
financial instrument
, type of instrument
ISIN: GB0033711010
Identification code
-------------------------------------- ----------------------------------------
b) Nature of the transaction Subscription for new Ordinary Shares
-------------------------------------- ----------------------------------------
c) Price(s) and volume(s) Price Volume
-------------------------------------- ------------------ --------------------
5 pence 1,200,000
-------------------------------------------------------------- --------------------
d) Aggregated information N/A
- Aggregated volume
- Price
-------------------------------------- ----------------------------------------
e) Date of the transaction 10 August 2022
-------------------------------------- ----------------------------------------
f) Place of the transaction Off market
-------------------------------------- ----------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Ms Lisa Baderoon
---------------------------------------- ----------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------------
a) Position / status Non - Executive Director
---------------------------------------- ----------------------------------------
b) Initial notification Initial notification
/ Amendment
---------------------------------------- ----------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------------
a) Name ImmuPharma PLC
---------------------------------------- ----------------------------------------
b) LEI 213800VZKGHXC7VUS895
---------------------------------------- ----------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----------------------------------------------------------------------------------
a) Description of the Ordinary Shares of 1p each
financial instrument
, type of instrument
ISIN: GB0033711010
Identification code
---------------------------------------- ----------------------------------------
b) Nature of the transaction Subscription for new Ordinary Shares
---------------------------------------- ----------------------------------------
c) Price(s) and volume(s) Price Volume
---------------------------------------- --------------------- -----------------
5 pence 400,000
------------------------------------------------------------------- -----------------
d) Aggregated information N/A
- Aggregated volume
- Price
---------------------------------------- ----------------------------------------
e) Date of the transaction 10 August 2022
---------------------------------------- ----------------------------------------
f) Place of the transaction Off market
---------------------------------------- ----------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Tim Franklin
---------------------------------------- ----------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------------
a) Position / status Chief Operating Officer
---------------------------------------- ----------------------------------------
b) Initial notification Initial notification
/ Amendment
---------------------------------------- ----------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------------
a) Name ImmuPharma PLC
---------------------------------------- ----------------------------------------
b) LEI 213800VZKGHXC7VUS895
---------------------------------------- ----------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----------------------------------------------------------------------------------
a) Description of the Ordinary Shares of 1p each
financial instrument
, type of instrument
ISIN: GB0033711010
Identification code
---------------------------------------- ----------------------------------------
b) Nature of the transaction Subscription for new Ordinary Shares
---------------------------------------- ----------------------------------------
c) Price(s) and volume(s) Price Volume
---------------------------------------- --------------------- -----------------
5 pence 400,000
------------------------------------------------------------------- -----------------
d) Aggregated information N/A
- Aggregated volume
- Price
---------------------------------------- ----------------------------------------
e) Date of the transaction 10 August 2022
---------------------------------------- ----------------------------------------
f) Place of the transaction Off market
---------------------------------------- ----------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSFDEESEESEEA
(END) Dow Jones Newswires
August 11, 2022 02:00 ET (06:00 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024
